5 years ago

Liverpool ChiroChem Secures £2.25 Million Funding for Drug Development

  • Liverpool ChiroChem (LCC), a UK-based developer and manufacturer of chemical components for the research and development of new drugs, secured £2.25 million in funding led by Deepbridge Capital and Praetura Ventures with participation from NPIF – Maven Equity Finance

  • The company intends to use the funds to accelerate growth

  • LCC is a chemistry-based contract research organization (CRO) that produces and supplies chiral small molecules to the global pharmaceutical and biotech research and development sector

  • Its goal is to accelerate the discovery and development of new drugs across multiple therapeutic areas including dementia, cancer and respiratory conditions

  • The business supports a global customer base from its research and development headquarters in Liverpool and its manufacturing facility in Taizhou, China.

      • Problembiotechnology

      "accelerating the discovery and development of new drugs across multiple therapeutic areas including dementia, cancer and respiratory conditions"

      Solution

      "provides chiral small molecules to the global pharmaceutical and biotech research and development sector"

      Covered on